19.3 C
New York
Tuesday, June 9, 2026

Tag: antibodies

newssourceFORcompanyinformationcontent1marketreleases

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/...

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. 
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.

Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology Consulting

The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of...

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in...

Chromatography Resin Market worth $4.94 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...

Chromatography Resin Market worth $4.94 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases.

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAntibodies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers